Centogene CentoMetabolic Panel
Centogene has launched its CentoMetabolic panel, a first-line test for a range of rare genetic metabolic diseases. According to Centogene, the panel combines genetic and biochemical testing, allowing immediate confirmation of and better understanding of a disease's course, enhanced treatment monitoring, and tailored treatment guidance. The panel includes as many as 166 genes and was developed for patients suspected to have a metabolic disorder or presenting complex, overlapping symptoms, a metabolic crisis, or neurological conditions of unknown etiology. The firm said that the panel provides short turnaround times, targets critically ill patients, includes enzyme-activity testing and a continually updating set of biomarkers.
Ares Genetics AresUPA NGS Service
Curetis subsidiary Ares Genetics announced today that it will launch a next-generation sequencing service in mid-2019 using its AresUPA Universal Pathogenome Assay, which can be used to sequence bacterial strains isolated from clinical specimens. According to the firm, AresUPA identifies the bacterial strain and detects antimicrobial resistance based on the genetic profile in the clinical isolate. The assay integrates NGS with data analysis and interpretation powered by ARESdb, the firm's AI-powered reference database on antimicrobial resistance genetics. Ares will offer the assay out of its NGS service laboratory currently being set up in Vienna, Austria.
Enpicom has introduced ImmunoGenomiX, an immune sequencing data analysis platform. Known as IGX, the platform will help researchers manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T-cell and B-cell receptors. The Netherlands-based company unveiled IGX at the Sixth Immunotherapy of Cancer Conference in Vienna, Austria.
For more new products and services, please visit the New Products page on our website.